Cepheid (CPHD +1%) continues its upward trajectory today, having gained over 17% since last...

|By:, SA News Editor

Cepheid (CPHD +1%) continues its upward trajectory today, having gained over 17% since last Thursday. Credit Suisse says it remains a top SMID cap pick given its best-in-class diagnostic testing platform and strong secular growth trends. Shares are Outperform rated with a $45 price target.